Henry Schein Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. We'll kick this off. Good morning, and welcome to the Jefferies Global Healthcare Conference in London. My name is Mike Sarcone, and I'm an analyst on the U.S. Medical Supplies and Devices team here, and this is a session with Henry Schein. From the company, we have Fred Lowery, CEO, Emmanuel Caprais, CFO, and Graham Stanley, who heads IR. Gentlemen, thank you very much for joining us today.
Good morning. Yeah, thanks for having us.
Awesome. I guess just to kick it off, Fred, we can start with you. You've been in the seat about nine months now. I guess, maybe give us an update on how your experience has been in the first nine months, and any surprises you've experienced to the upside or downside versus your expectations coming in.
Yeah, thanks for having us today. Excited to be here, and I would tell you, coming into the role, I was very excited to join Henry Schein, an iconic brand in the space, and really the leader in this space. I was excited about the opportunity, but I will tell you, eight months into the role, I am even more excited than I was coming in the door, and it is because of a few things. One, I have obviously learned a lot more about the business and about the industry, but I see even more opportunity, and it starts for us with our technology business. I mean, we have a great presence there. We are seeing very good growth.
What is really exciting is that the capabilities that we are adding to the platform, to our PMS platform, are really being accepted by customers, and I think that bodes well for continued growth in that space. Ultimately, it becomes the centerpiece of the platform that we are building to support our customers, and so that we are more than just a supplier, but more of a partner in helping them improve their practices. It starts with our technology business, but it continues through our service business, through our specialty products business, and of course, through our distribution business. So, I am even more bullish eight months into the role, and we are making good progress. We are taking market share in dental, and we are committed to deliver on our value creation actions that are helping us expand our operating income.
I feel like we are in a great spot, and the future is bright.
All right, great. Good to hear. Maybe, on the high-level strategy question, wanted to touch on Schein's BOLD+1 strategy. A big piece of this, though not the only piece, is shifting the mix toward higher growth, higher margin businesses. I guess, can you give us an update on where Schein stands in that journey today, and what are the competitive advantages that support that shift?
Yeah, so our stated goal was that we would get to over 50% of our income coming from high-growth and high-margin products by 2027, and we are on track to do that. We will X this year at that rate. I would also say it is not done. That mix shift that we are seeing to our high-growth, high-margin businesses will continue. I just spoke about our technology business, our PMS platform, where we are seeing good growth, both from a share of wallet standpoint and from new placements of our cloud-based platform, both the Dentrix Ascend and Dentally platforms. So, that will continue, and we will see good growth in our specialty products, which is another portion of our high-growth, high-margin business, where we are seeing good growth in our implant business in Europe. We are seeing good growth in our value implant business in the U.S.
We are very excited about the SIN 360 business, and we are seeing new products being launched into that business. We feel good about us continuing to see that mix shift into high-growth, high-margin as a part of our operating income.
All right, great. Maybe we can loop in Emmanuel. You are a few weeks into the role. I guess first, can you talk about what attracted you to Schein, and then second, can you talk about how your background and experience make you well-positioned to execute on key priorities at Schein?
Yeah, thank you, Mike. I think what attracted me was to join a market-leading healthcare platform. We have a very capillary distribution network. Henry Schein has a lot of competitive advantages, and so being able to contribute to that was really attracting to me. So, driving growth, driving profitable growth, driving cash generation are going to be my focus in supporting Fred to implement his mission and his vision. I think in terms of my industrial background, I come from a place where we drive profitable growth. We are very focused on cash, and so that is what I intend to implement and to help drive at Henry Schein. I think this is a company that has a lot of really strong positions and very passionate people.
I think that when you have a lot of competence to work with, you can direct and guide people in a more effective way and make up a little bit for that maybe developing market knowledge, the situation that I'm in. I think that great base to work with, looking forward to add and drive profitable growth as well as cash generation.
All right, thank you for that. I guess just to squeeze one in, we saw an update yesterday from Schein about taking out the remeasurement gains and rebasing some of the P&L. I guess, can you speak to the timing around that and what you hope to accomplish?
Yeah. I think, I realize that the remeasurement gains are providing difficult readability of legibility of the numbers. It's very lumpy, so it didn't really belong to operational performance, so that's why we decided to exclude them for our results. We think it's going to provide a more direct read on how the company is performing. For us, that was the first step, small first step to show the operational improvement in the operational discipline that we want to instill in the business. Yeah, I think, I wouldn't say it's a major change.
It's just providing better visibility to our operational performance, then I think that this is what we intend to do. We intend to drive really good results and then be able to simply explain how we're doing that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
